Format

Send to

Choose Destination
Expert Rev Vaccines. 2003 Jun;2(3):447-59.

Alphavirus vectors for vaccine production and gene therapy.

Author information

1
Regulon Inc., Epalinges, Switzerland. kenneth.lundstrom@mepnet.org

Abstract

Alphavirus vectors demonstrate high expression of heterologous proteins in a broad range of host cells. Replication-deficient as well as replication-competent variants exist. Systemic delivery of many viral antigens has elicited strong antibody responses in immunized mice and primates, and protection against challenges with lethal viruses was obtained. Similarly, prophylactic vaccination was established against tumor challenges. Attention has been paid to the engineering of improved targeting to immunologically active cells, such as dendritic cells. In the area of gene therapy, intratumoral injections of alphavirus vectors have resulted in potentially promising tumor rejection. Moreover, encapsulation of alphavirus particles into liposomes demonstrated efficient tumor targeting in mice with severe combined immunodeficiency, which permitted the initiation of clinical trials for patients with advanced kidney carcinoma and melanoma.

PMID:
12903809
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center